Abstract
Cardiovascular diseases (CVDs) remain a leading cause of global mortality. As the burden of these diseases continues to rise, the development of innovative therapeutic agents has become increasingly important. Honokiol, a bioactive compound extracted from the bark and leaves of particular Magnolia species, has garnered attention for its wide-ranging pharmacological effects, including anti-inflammatory, antioxidant, and vasodilatory properties. Emerging research suggests that honokiol holds significant promise as a therapeutic agent for managing CVDs. The present review provides a comprehensive overview of the bioactive properties, cardiovascular effects, mechanisms of action, and potential clinical utility of honokiol for the treatment of CVDs. Furthermore, challenges and future directions for the clinical translation of honokiol are discussed at length to provide additional context.